SEC Form 4 · accession 0001458643-26-000004
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bhaskar Chaudhuri
Director
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819790
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $64.34 | Jun 25, 2026 | A | 3,837 | A | — | Jun 24, 2036 | Common Stock | 3,837 | 3,837 | D |
| Restricted Stock UnitsF2,F3 | — | Jun 25, 2026 | A | 2,417 | A | — | — | Common Stock | 2,417 | 2,417 | D |
Explanation of responses
- F1Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- F3RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.